Press Releases

July 22, 2026

• Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management

• July 14, 2026

• Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development

• July 12, 2026

• Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases

• July 08, 2026

• Insilico Medicine Releases Positive Profit Alert for the First Half of 2026

• July 07, 2026

• Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

• July 06, 2026

• Pharma.AI Q2 2026 Summer Webinar: A Deep Dive into Insilico Medicine’s Latest Platform Upgrades

2023

• Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target 10-JANUARY-2023

• Insilico announces the expansion of its oncology pipelines and delivers the new generation FGFR2/3 inhibitor 28 December 2023

• Insilico announces the second generation DGKA inhibitor for the treatment of PD-1/PD-L1 resistance solid tumors 26 December 2023

• Insilico Medicine leadership to attend 42nd Annual J.P. Morgan Healthcare Conference 18 December 2023

• Insilico Medicine announces AI drug discovery milestone achievement in pharma collaboration 12 December 2023

2022

• Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation 05-JAN-2022

• Insilico Medicine nominates potential first-in-class preclinical candidate with novel AI-designed structure for novel AI-discovered target in immuno-oncology 20-DECEMBER-2022

• Insilico Medicine Awarded Over $700,000 to Design New Contraceptive Options with AI 16-NOVEMBER-2022

• Insilico Medicine receives Company of the Year Award at BioCentury-BayHelix East-West Summit 16-NOVEMBER-2022

• Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion 8-NOVEMBER-2022

• Deepfake Technology in Drug Design. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event 20-OCTOBER-2022

• Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities 10-SEPTEMBER-2022

• Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million 10-AUGUST-2022

• Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine 07-JULY-2022

• Insilico Medicine appoints Dr. Feng Ren as co-CEO 16-JUNE-2022

• Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Automated Laboratory 06-JUNE-2022

• Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment 24-MAY-2022

• CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World 17-MAY-2022

• Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers 05-MAY-2022

• Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders 13-APR-2022

• Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform 25-JAN-2022

• Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets 11-JAN-2022

• Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference 06-JAN-2022